JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5676
Momentus
MNTS
$82.6M
| $65.8K | ﹤0.01% |
+465
| New | +$65.4K |
2023 Q3
5 quarters
|
|
5677
FT Vest US Equity Deep Buffer ETF September
DSEP
$379M
| $65.8K | ﹤0.01% |
+1,623
| New | +$65.7K |
2024 Q4
0 quarters
|
|
5678
State Street SPDR S&P Global Infrastructure ETF
GII
$899M
| $65.8K | ﹤0.01% |
1,112
+1
| +0.1% | +$61 |
2024 Q1
3 quarters
|
|
5679
PUT
West Pharmaceutical
WST
$25.7B
| $65.5K | ﹤0.01% |
200
-700
| -78% | -$220K |
2023 Q4
4 quarters
|
|
5680
AmeriServ Financial
ASRV
$75.6M
| $65.5K | ﹤0.01% |
25,000
| – | – |
2024 Q3
1 quarter
|
|
5681
First Trust Dow Jones Global Select Dividend Index Fund
FGD
$1.54B
| $65.2K | ﹤0.01% |
2,930
| – | – |
2023 Q2
6 quarters
|
|
5682
AllianzIM U.S. Equity 6 Month Buffer10 Apr/Oct ETF
SIXO
$120M
| $64.8K | ﹤0.01% |
2,000
-7,089
| -78% | -$229K |
2024 Q3
1 quarter
|
|
5683
Lexicon Pharmaceuticals
LXRX
$810M
| $64.7K | ﹤0.01% |
87,617
-2,083
| -2% | -$2.51K |
2015 Q3
37 quarters
|
|
|
GUG
5684
Guggenheim Active Allocation Fund
GUG
$460M
| $64.7K | ﹤0.01% |
4,350
+550
| +14% | +$8.63K |
2024 Q3
1 quarter
|
|
5685
Douglas Elliman
DOUG
$138M
| $64.4K | ﹤0.01% |
38,560
+17,027
| +79% | +$32.7K |
2021 Q4
12 quarters
|
|
5686
Blink Charging
BLNK
$77M
| $64.4K | ﹤0.01% |
46,307
+533
| +1% | +$941 |
2020 Q2
18 quarters
|
|
|
QVCGA
5687
DELISTED
QVC Group Inc Series A
QVCGA
| $64.3K | ﹤0.01% |
3,895
-963
| -20% | -$22.5K |
2013 Q2
46 quarters
|
|
5688
iShares MSCI Netherlands ETF
EWN
$696M
| $64K | ﹤0.01% |
1,438
+50
| +4% | +$2.34K |
2021 Q2
14 quarters
|
|
5689
T. Rowe Price US Equity Research ETF
TSPA
$4.55B
| $63.6K | ﹤0.01% |
1,719
+1,554
| +942% | +$57.7K |
2024 Q3
1 quarter
|
|
5690
MediWound
MDWD
$178M
| $63.5K | ﹤0.01% |
3,568
+167
| +5% | +$2.88K |
2023 Q4
4 quarters
|
|
5691
Spero Therapeutics
SPRO
$73.4M
| $63.5K | ﹤0.01% |
61,624
+61,388
| +26,012% | +$73K |
2017 Q4
28 quarters
|
|
5692
PUT
Fastly Inc
FSLY
$4.2B
| $63.2K | ﹤0.01% |
6,700
| – | – |
2024 Q1
3 quarters
|
|
5693
Hamilton Beach Brands
HBB
$499M
| $63.2K | ﹤0.01% |
3,755
+119
| +3% | +$2.75K |
2017 Q4
28 quarters
|
|
5694
Innovator US Equity Power Buffer ETF September
PSEP
$1.15B
| $63K | ﹤0.01% |
1,613
-504
| -24% | -$19.6K |
2024 Q3
1 quarter
|
|
5695
PUT
KLA
KLAC
$261B
| $63K | ﹤0.01% |
1,000
-3,000
| -75% | -$203K |
2024 Q2
2 quarters
|
|
5696
ALPS Active Equity Opportunity ETF
RFFC
$30.6M
| $62.5K | ﹤0.01% |
1,080
| – | – |
2022 Q4
8 quarters
|
|
|
SMAX
5697
iShares Large Cap Max Buffer Sep ETF
SMAX
$89M
| $62.5K | ﹤0.01% |
+2,480
| New | +$62.4K |
2024 Q4
0 quarters
|
|
5698
Corbus Pharmaceuticals
CRBP
$123M
| $62.3K | ﹤0.01% |
5,277
-230
| -4% | -$3.86K |
2017 Q4
28 quarters
|
|
5699
PUT
Herbalife
HLF
$1.29B
| $62.2K | ﹤0.01% |
9,300
-69,900
| -88% | -$519K |
2024 Q1
3 quarters
|
|
5700
Eaton Vance Tax-Managed Diversified Equity Income Fund
ETY
$2.24B
| $62.1K | ﹤0.01% |
4,154
+1,700
| +69% | +$25.3K |
2022 Q4
8 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.